Daniel (Dan) Wang applies his experience with opioids, stimulants, and other CNS-active compounds to lead efforts on the development of CBD and other cannabinoids and new dietary ingredients, providing clients with valuable policy and regulatory perspectives in this rapidly evolving area. In this role, Dan currently:
- Provides policy and regulatory guidance to companies seeking to market cannabinoids and new dietary ingredients
- Contributes to reports and manuscript publications on abuse potential of CNS-active products
- Assesses changes in the regulatory landscape surrounding novel therapeutics such as cannabinoids and other botanically derived health products
Before joining PinneyAssociates in 2010, Dan coordinated early phase clinical trials in oncologic drug development at the Hospital of the University of Pennsylvania.
At PinneyAssociates, for over ten years, Dan has provided scientific and regulatory support for companies developing and marketing drugs and other products with abuse potential. He has presented and co-authored a number of articles on the abuse potential of novel botanical products, including kratom, and real-world outcomes of use of these products.
- Graduated with a bachelor’s in the biological basis of behavior from the University of Pennsylvania